TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33771716

Group type: EXPERIMENTAL
Intervention: Itraconazole coadministration (Period II)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (Period I, no itraconazole)
Number of subjects: 0
Study: 32281817

Group type: EXPERIMENTAL
Intervention: Inhibitory control training (ICT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control/sham training
Number of subjects: 60
Study: 35247167

Group type: EXPERIMENTAL
Intervention: Stability-based training with visualisation (VIS) for 4 weeks
Number of subjects: 17

Group type: COMPARATOR
Intervention: Stability-based training without visualisation (NO-VIS) for 4 weeks
Number of subjects: 17
Study: 32975161

Group type: EXPERIMENTAL
Intervention: Ureteral catheter treatment
Number of subjects: 6459

Group type: COMPARATOR
Intervention: Control group (no APN)
Number of subjects: 6459
Study: 32375605

Group type: EXPERIMENTAL
Intervention: ECG group (IC-ECG method)
Number of subjects: 2250

Group type: COMPARATOR
Intervention: Control group (traditional landmark length estimation)
Number of subjects: 2250

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2250

Group type: EXPERIMENTAL
Intervention: ECG group
Number of subjects: 2250
Study: 35988167

Group type: EXPERIMENTAL
Intervention: CNP‐EPI (1 mL subcutaneously injected 1 day before surgery)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 60
Study: 34507350

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Number of subjects: 128

Group type: COMPARATOR
Intervention: Physician's choice (methotrexate or bexarotene)
Number of subjects: 128
Study: 34252556

Group type: EXPERIMENTAL
Intervention: Osteochondroplasty
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lavage (control group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Osteochondroplasty (RCT group)
Number of subjects: 0
Study: 34252267

Group type: EXPERIMENTAL
Intervention: Horyzons online therapy
Number of subjects: 12
Study: 34706047

Group type: EXPERIMENTAL
Intervention: Music (15 minutes) plus swaddling
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Music (10 minutes) plus swaddling
Number of subjects: 52

Group type: COMPARATOR
Intervention: No music (10 minutes) plus swaddling
Number of subjects: 52

Group type: COMPARATOR
Intervention: No music (15 minutes) plus swaddling
Number of subjects: 52
Study: 32374527

Group type: COMPARATOR
Intervention: IBWL (Internet-Based Weight Loss)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: IBWL + $ (Internet-Based Weight Loss with Financial Incentives)
Number of subjects: 180
Study: 33098434

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (2000 IU/day)
Number of subjects: 1312

Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (1 g/day)
Number of subjects: 1312

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1312
Study: 35578253

Group type: EXPERIMENTAL
Intervention: Group 1 (n = 176) evaluated with exploratory factor analysis
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Group 2 (n = 176) evaluated with confirmatory factor analysis
Number of subjects: 352

Group type: COMPARATOR
Intervention: Participants performing traditional menstrual practices
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Negative menstrual attitudes
Number of subjects: 352
Study: 616407122

Group type: EXPERIMENTAL
Intervention: Combined rehabilitation exercise program and prolotherapy (EPG)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Rehabilitation exercise program alone (EG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Prolotherapy alone (PG)
Number of subjects: 30
Study: 34775857

Group type: EXPERIMENTAL
Intervention: Nutrition education and counseling intervention
Number of subjects: 235

Group type: COMPARATOR
Intervention: Control group (no nutrition education and counseling)
Number of subjects: 235
Study: 32869361

Group type: EXPERIMENTAL
Intervention: Consumption of poultry
Number of subjects: 986

Group type: COMPARATOR
Intervention: No poultry consumption (Control)
Number of subjects: 986

Group type: COMPARATOR
Intervention: Consumption of pork, beef, lamb, processed meat, total meat
Number of subjects: 986
Study: 32468765

Group type: EXPERIMENTAL
Intervention: Prophylactic pre-operative antibiotics
Number of subjects: 121

Group type: COMPARATOR
Intervention: No pre-operative antibiotics
Number of subjects: 121
Study: 36443769

Group type: EXPERIMENTAL
Intervention: Empagliflozin (Group-A)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Standard care (Group-B)
Number of subjects: 244
Study: 33782684

Group type: EXPERIMENTAL
Intervention: Salt substitute (70% sodium chloride/30% potassium chloride blend)
Number of subjects: 502

Group type: COMPARATOR
Intervention: Regular salt (100% sodium chloride)
Number of subjects: 502
Study: 32043808

Group type: EXPERIMENTAL
Intervention: Zheng's Supine Rehabilitation Exercise (ZSRE)
Number of subjects: 82
Study: 35939865

Group type: EXPERIMENTAL
Intervention: Probiotic treatment (Lacticaseibacillus paracasei SD1, L. rhamnosus SD4, L. rhamnosus SD11, Limosilactobacillus fermentum SD7)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 20
Study: 34276009

Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors (canagliflozin 100 mg/day or dapagliflozin 5 mg/day or empagliflozin 10 mg/day)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors
Number of subjects: 81
Study: 32621449

Group type: EXPERIMENTAL
Intervention: Razi vaccine
Number of subjects: 14250

Group type: EXPERIMENTAL
Intervention: Dn vaccine
Number of subjects: 14250

Group type: EXPERIMENTAL
Intervention: Vc vaccine
Number of subjects: 14250

Group type: EXPERIMENTAL
Intervention: Ch vaccine
Number of subjects: 14250
Study: 35652323

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (LI) involving cognitive behavioral therapy (CBT)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (LI) involving CBT with additional short message service (SMS)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Control (care as usual [CAU])
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Higher baseline weight
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Higher levels of androstenedione
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Higher depression scores
Number of subjects: 183
Study: 33905962

Group type: EXPERIMENTAL
Intervention: Ramucirumab plus erlotinib (RAM + ERL)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo plus erlotinib (PBO + ERL)
Number of subjects: 113
Study: 35218191

Group type: COMPARATOR
Intervention: l-methionine (reference diet) at 0.5, 1, 2, and 3 mg.kg-1.d-1
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Cooked lentils + rice (test diets)
Number of subjects: 5
Study: 33397427

Group type: EXPERIMENTAL
Intervention: High-dose heparinization aiming for an activated clotting time (ACT) of 140–180 s
Number of subjects: 218

Group type: COMPARATOR
Intervention: Low-dose heparinization aiming for a partial thromboplastin time (PTT) of 35–40 s
Number of subjects: 218
Study: 35367069

Group type: EXPERIMENTAL
Intervention: fIPV-dmLT
Number of subjects: 29

Group type: COMPARATOR
Intervention: fIPV
Number of subjects: 29
Study: 33548518

Group type: EXPERIMENTAL
Intervention: Tree SLIT-tablet (12 SQ-Bet)
Number of subjects: 634

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 634
Study: 36064525

Group type: EXPERIMENTAL
Intervention: Genetically-proxied beta-blocker (BB)
Number of subjects: 4743

Group type: EXPERIMENTAL
Intervention: Genetically-proxied calcium channel blocker (CCB)
Number of subjects: 4743
Study: 33370444

Group type: EXPERIMENTAL
Intervention: Embedded athletic training musculoskeletal care model (2 certified athletic trainers and a sports medicine fellowship‐trained physician)
Number of subjects: 0
Study: 36404525

Group type: EXPERIMENTAL
Intervention: Futibatinib 20 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Futibatinib 80 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: COMPARATOR
Intervention: Moxifloxacin (positive control)
Number of subjects: 48
Study: 33565691

Group type: EXPERIMENTAL
Intervention: Liraglutide (1.8 mg once-daily)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Sitagliptin (100 mg once-daily)
Number of subjects: 61
Study: 32653447

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 4744

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4744
Study: 36179323

Group type: EXPERIMENTAL
Intervention: Transient Events (TEs; less than 60 seconds)
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Prolonged Events (PEs; 60 seconds or longer)
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Prolonged Events (PEs) during nursing shift 2 (3 pm to 11 pm)
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Rate of TEs within PEs
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Activity levels during nursing shifts
Number of subjects: 1100
Study: 35583344

Group type: EXPERIMENTAL
Intervention: Rifampicin (RIF) added to DRV/r 800/100 mg once daily (QD) and then DRV/r 800/100 twice daily (BD) and 1,600/200 QD
Number of subjects: 17

Group type: COMPARATOR
Intervention: DRV/r 800/100 mg once daily (QD)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Rifampicin (RIF)
Number of subjects: 17
Study: 33191251

Group type: EXPERIMENTAL
Intervention: Permissive hypotension (vasopressor titration to achieve MAP 60-65 mm Hg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 7
Study: 33689654

Group type: EXPERIMENTAL
Intervention: Active treatment videogame
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo videogame
Number of subjects: 105
Study: 35278698

Group type: EXPERIMENTAL
Intervention: Provided vegetable intervention
Number of subjects: 51
Study: 32996027

Group type: EXPERIMENTAL
Intervention: Daily SMS with self-care guidelines for managing side effects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no SMS intervention)
Number of subjects: 0
Study: 32353079

Group type: EXPERIMENTAL
Intervention: Weight loss maintenance intervention
Number of subjects: 1421
Study: 34562610

Group type: EXPERIMENTAL
Intervention: Nivolumab (1 mg/kg, Q3W) plus ipilimumab (3 mg/kg, Q3W) followed by nivolumab monotherapy (240 mg, Q2W) for up to 12 months
Number of subjects: 153

Group type: COMPARATOR
Intervention: Observation (no treatment)
Number of subjects: 153
Study: 33002868

Group type: EXPERIMENTAL
Intervention: Subperiosteal drain (SPD)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Subdural drain (SDD)
Number of subjects: 104
Study: 36267318

Group type: EXPERIMENTAL
Intervention: Narcotrend (NT) group (supervised anesthesia under NT monitoring)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group (anesthesia according to doctors' experience)
Number of subjects: 144
Study: 34453234

Group type: EXPERIMENTAL
Intervention: Favipiravir (1800 mg twice a day on Day 1, followed by 800 mg twice a day for up to 13 days)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Favipiravir
Number of subjects: 156
Study: 34049120

Group type: EXPERIMENTAL
Intervention: Immersive 3D interactive video program
Number of subjects: 45

Group type: COMPARATOR
Intervention: Regular demonstration video
Number of subjects: 45
Study: 33416742

Group type: EXPERIMENTAL
Intervention: Physician + patient intervention
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: Physician‐only intervention
Number of subjects: 538

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 538
Study: 36374742

Group type: EXPERIMENTAL
Intervention: drug-laser-photon therapy
Number of subjects: 75
Study: 36254422

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 25 mcg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 50 mcg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 75 mcg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 100 mcg
Number of subjects: 150

Group type: COMPARATOR
Intervention: Normal Saline (Control)
Number of subjects: 150
Study: 33883768

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8mg (2mls of 4mg/ml)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo (2mls of saline)
Number of subjects: 94
Study: 33358704

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01E vaccine
Number of subjects: 95

Group type: COMPARATOR
Intervention: Comparator vaccine
Number of subjects: 95
Study: 33021328

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) administered early, <3h post-injury
Number of subjects: 12737

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12737
Study: 35129000

Group type: EXPERIMENTAL
Intervention: Intermittent kangaroo care for 30 minutes once a day for 10 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study: 34037993

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 3716
Study: 32635281

Group type: EXPERIMENTAL
Intervention: Aquatic Ai Chi therapy
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Combined therapy (alternating sessions of physiotherapy on dry land and aquatic Ai Chi therapy)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Physiotherapy treatment on dry land (control group)
Number of subjects: 45
Study: 34930688

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention strategy (exercise, diet, peer education)
Number of subjects: 2005

Group type: COMPARATOR
Intervention: General health education (control group)
Number of subjects: 2005

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 2005
Study: 32910169

Group type: EXPERIMENTAL
Intervention: Meta-i6mA
Number of subjects: 3
Study: 34091420

Group type: EXPERIMENTAL
Intervention: Encorafenib plus binimetinib
Number of subjects: 577
Study: 32502179

Group type: EXPERIMENTAL
Intervention: Bevacizumab 0.05% eye drops (n = 19)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (n = 12)
Number of subjects: 31
Study: 35523753

Group type: EXPERIMENTAL
Intervention: Plastic surgical repair of DF ulcers
Number of subjects: 112

Group type: COMPARATOR
Intervention: Drug treatment
Number of subjects: 112
Study: 32343909

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Exercise (HIIE; 25 min including ten 1-min intervals at 85% heart rate reserve)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Exercise (MICE; 45 min at 50% heart rate reserve)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (30 min quiet rest)
Number of subjects: 9
Study: 33059781

Group type: EXPERIMENTAL
Intervention: Dietary changes observed at T2 (2014-2018) compared to T1 (2001-2004)
Number of subjects: 2569

Group type: EXPERIMENTAL
Intervention: Dietary GHGE from animal-based foods
Number of subjects: 2569

Group type: EXPERIMENTAL
Intervention: Dietary GHGE from discretionary foods
Number of subjects: 2569

Group type: EXPERIMENTAL
Intervention: Prevalence of overweight
Number of subjects: 2569
Study: 35304020

Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Number of subjects: 80
Study: 32112136

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 36451279

Group type: EXPERIMENTAL
Intervention: Cash plus intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34352829

Group type: EXPERIMENTAL
Intervention: 12‐mL paracervical block
Number of subjects: 96

Group type: COMPARATOR
Intervention: 20‐mL paracervical block
Number of subjects: 96
Study: 36112084

Group type: EXPERIMENTAL
Intervention: HS-20090
Number of subjects: 154
Study: 34610481

Group type: EXPERIMENTAL
Intervention: Somnox sleep robot intervention
Number of subjects: 44

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 44
Study: 32693214

Group type: EXPERIMENTAL
Intervention: Continuation of stable dose of combination inhaled corticosteroid-long-acting beta-agonist
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Step-down of inhaled corticosteroid
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Discontinuation of long-acting bronchodilator
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: FENO levels measured serially at 6-week intervals
Number of subjects: 447
Study: 35501757

Group type: EXPERIMENTAL
Intervention: NOOM application
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Walkon application
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Efilcare application
Number of subjects: 320

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 320
Study: 34927230

Group type: EXPERIMENTAL
Intervention: Laparoscopic pyelolithotomy (LPL)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Percutaneous nephrolithotomy (PCNL)
Number of subjects: 68
Study: 34328442

Group type: EXPERIMENTAL
Intervention: Multimedia software platform for patient-reported outcomes (PRO) measures
Number of subjects: 120
Study: 32144908

Group type: EXPERIMENTAL
Intervention: Herbal cake-partitioned moxibustion combined with Rhinocort spray (256 µg/d, once in the morning and evening, for 4 weeks)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Rhinocort spray alone (256 µg/d, once in the morning and evening, for 4 weeks)
Number of subjects: 67
Study: 33780529

Group type: EXPERIMENTAL
Intervention: 6-month aerobic exercise intervention
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Recruitment strategies
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Referrals and Alzheimer's Association events/services
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Recruitment cost
Number of subjects: 96
Study: 33834214

Group type: EXPERIMENTAL
Intervention: Feeding at 1130 hours
Number of subjects: 24

Group type: COMPARATOR
Intervention: Feeding at 0730 hours (Control)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Feeding at 1530 hours
Number of subjects: 24
Study: 34649266

Group type: EXPERIMENTAL
Intervention: Time-restricted eating (TRE) diet
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal diet (ND)
Number of subjects: 20
Study: 32593524

Group type: EXPERIMENTAL
Intervention: Ursolic acid (UA) 400 mg/d
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo 400 mg/d
Number of subjects: 22
Study: 32305380

Group type: EXPERIMENTAL
Intervention: Equia Fil
Number of subjects: 34

Group type: COMPARATOR
Intervention: Fuji IX GP Fast
Number of subjects: 34
Study: 34919621

Group type: EXPERIMENTAL
Intervention: Low-speed drilling protocol without saline irrigation
Number of subjects: 23

Group type: COMPARATOR
Intervention: Standard drilling protocol
Number of subjects: 23
Study: 35258444

Group type: EXPERIMENTAL
Intervention: ePNa (electronic pneumonia clinical decision support)
Number of subjects: 6848
Study: 36089810

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg once daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg once daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg + Losartan 50 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 24
Study: 32239442

Group type: EXPERIMENTAL
Intervention: Video version of the survey
Number of subjects: 95

Group type: COMPARATOR
Intervention: Text version of the survey
Number of subjects: 95
Study: 35889757

Group type: EXPERIMENTAL
Intervention: Spelt bread (traditional recipe)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Spelt bread (current recipe)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Wheat bread (traditional recipe)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Wheat bread (current recipe)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: +FODMAP gluten-free bread
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: +Gluten gluten-free bread
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (wheat bread)
Number of subjects: 24
Study: 34180998

Group type: EXPERIMENTAL
Intervention: PCOS
Number of subjects: 1603

Group type: EXPERIMENTAL
Intervention: PCOS and elevated fasting insulin
Number of subjects: 1603

Group type: EXPERIMENTAL
Intervention: PCOS, elevated insulin, WC >88 cm, and current smoking
Number of subjects: 1603

Group type: EXPERIMENTAL
Intervention: Clinical depression score and PCOS diagnosis
Number of subjects: 1603

Group type: EXPERIMENTAL
Intervention: Short sleep duration and clinical symptoms of OSA
Number of subjects: 1603
Study: 32091443

Group type: EXPERIMENTAL
Intervention: Verum (Lactobacillus mixture)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study: 35926544

Group type: EXPERIMENTAL
Intervention: Balloon pulmonary angioplasty (BPA)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Riociguat
Number of subjects: 61
Study: 33866555

Group type: EXPERIMENTAL
Intervention: Minocycline microspheres application
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no minocycline microspheres)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 33971067

Group type: EXPERIMENTAL
Intervention: Ozone therapy (major autohemotherapy) applied to 37 patients, consisting of seven sessions of intravenous ozone administration (100 mL, 30 μg/mL)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Conventional COVID-19 treatment applied to 18 patients in the control group
Number of subjects: 55
Study: 32045945

Group type: EXPERIMENTAL
Intervention: Left hemispheric stimulation
Number of subjects: 15

Group type: COMPARATOR
Intervention: Right hemispheric stimulation
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both hemispheres
Number of subjects: 15
Study: 35234881

Group type: EXPERIMENTAL
Intervention: 12-month lifestyle intervention focused on diet and physical activity
Number of subjects: 1601

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1601
Study: 35169095

Group type: EXPERIMENTAL
Intervention: Bevacizumab, a humanized monoclonal antibody targeting vascular endothelial growth factor.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified.
Number of subjects: 0
Study: 33188747

Group type: EXPERIMENTAL
Intervention: Nitazoxanide (1.0 g/day) for 14 days
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Mesalazine (1.5-2 g/day) for 14 days
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combination of nitazoxanide (1.0 g/day) and mesalazine (≥1.5-2 g/day) for 14 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 100
Study: 32439340

Group type: EXPERIMENTAL
Intervention: Evolocumab (140mg; n=17)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Non-evolocumab (n=19)
Number of subjects: 36